ENTO
Entero Therapeutics, Inc. (ENTO) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity near 9.6% of revenue suggests a moderate innovation footprint, but peers with similar technology spend often disclose clearer emissions and resource targets.
Negative gross margin indicates limited operating efficiency, which can constrain funding for environmental programs relative to peers with stronger cash generation.
Low debt-to-equity and negative net debt support flexibility for sustainability investment, yet this balance-sheet strength is not itself an environmental differentiator versus peers.
No direct emissions, energy, or waste disclosures were provided, so environmental positioning versus peers remains difficult to verify and likely mid-pack.
Social
Stock-based compensation at 12.8% of revenue can align employees with long-term value creation, but it may also signal heavier dilution than better-aligned peers.
High R&D intensity can support workforce skill development and product safety, yet peers with stronger disclosure typically evidence broader human-capital metrics.
Negative gross margin may pressure staffing stability and training budgets, which can weaken social execution relative to peers with healthier operating buffers.
No data were provided on turnover, safety, diversity, or community practices, leaving social performance largely unsubstantiated versus peers.
Governance
Low debt-to-equity suggests conservative capital structure, which generally reduces creditor pressure and supports governance flexibility versus more levered peers.
Stock-based compensation at 12.8% of revenue indicates meaningful equity incentives, but peers with lower dilution often show stronger capital-allocation discipline.
R&D intensity near 9.6% of revenue can reflect strategic reinvestment, though peers with clearer oversight usually pair it with more transparent milestone disclosure.
Absent board, audit, and ownership data, governance quality cannot be confirmed, so relative positioning remains moderate rather than strong.
Overall Score
ENTO appears broadly mid-pack on ESG relative to peers because available metrics show some balance-sheet and innovation strengths, but disclosure gaps limit evidence of stronger positioning.
Score Driver: Limited ESG Disclosure Prevents Confirmation Of A Peer-Leading Position.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Entero Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
